Summary
Dexcom presented groundbreaking research at the 2025 ADA Scientific Sessions, revealing that healthcare professionals favor CGM over medication advancements for future Type 2 diabetes care. The company’s “State of Type 2 Report” highlighted the potential of CGM to transform diabetes management, supported by clinical data demonstrating reduced mortality risk and improved patient outcomes. Dexcom also showcased its latest advancements, including the highly accurate G7 15-Day CGM and innovative partnerships.
See how TrueNAS offers real-time support for healthcare data managers.
** Main Story**
Dexcom’s Impactful Presence at ADA 2025: A New Era for Type 2 Diabetes Management
Dexcom made a significant impact at the 2025 American Diabetes Association (ADA) Scientific Sessions, held in Chicago from June 20-23, by presenting a new report and extensive clinical data highlighting the transformative potential of continuous glucose monitoring (CGM) in Type 2 diabetes care. The company’s “Dexcom State of Type 2 Report: Access and Attitudes Across the United States” revealed a significant shift in healthcare professionals’ perspectives, with a majority now favoring CGM over medication advancements for the future of Type 2 diabetes management.
Healthcare Professionals Embrace CGM as the Future of Type 2 Care
The “State of Type 2 Report,” based on a survey of over 400 healthcare professionals (HCPs) and individuals with Type 2 diabetes across the U.S., unveiled several key findings. Notably, 59% of HCPs believe that improved access to CGM will be the most effective approach to managing Type 2 diabetes over the next decade, surpassing advancements in diabetes medications. This shift in perspective reflects the growing recognition of CGM’s ability to provide real-time glucose data and personalized insights, empowering patients to make informed decisions about their health. Furthermore, an overwhelming majority of HCPs (96%) support CGM as the standard of care for individuals using multiple daily insulin injections, with 94% advocating for its use in those on basal insulin. The report also indicated unanimous support (100%) among surveyed HCPs for integrating CGM with GLP-1 or SGLT2 medications.
Clinical Data Reinforces CGM’s Benefits in Improving Patient Outcomes
Dexcom’s presentations at ADA 2025 showcased compelling clinical data further validating the benefits of CGM for individuals with Type 2 diabetes. Studies presented at the conference demonstrated a significant reduction in mortality risk among insulin-using individuals with Type 2 diabetes who utilized CGM compared to those relying on traditional self-monitoring of blood glucose (SMBG). Moreover, real-world observational studies of individuals with Type 2 diabetes not using insulin revealed that Dexcom G7 use led to significantly reduced diabetes-related distress and increased adherence to healthy eating plans and exercise routines. These findings underscore CGM’s potential as a powerful tool for behavior modification and improved self-management.
Dexcom Showcases Latest Innovations and Partnerships
Beyond the report and clinical data, Dexcom showcased its latest advancements in CGM technology at ADA 2025. The company highlighted its G7 15-Day CGM system, which boasts an overall mean absolute relative difference (MARD) of 8.0%, making it one of the most accurate CGM systems available. Dexcom also emphasized its commitment to connectivity, demonstrating new integrations with automated insulin delivery systems and smart insulin pens. The company’s recent partnership with ŌURA Ring, a wearable health technology company, further expands its reach in the diabetes management space. This collaboration aims to provide individuals with more holistic insights into their metabolic health by integrating Dexcom’s glucose data with biometrics collected by the ŌURA Ring.
A Call for Broader Access to CGM
The findings from Dexcom’s “State of Type 2 Report” and the compelling clinical data presented at ADA 2025 provide a strong argument for broader access to CGM technology. The information reinforces the notion that CGM should be considered a standard of care for all individuals with Type 2 diabetes, regardless of insulin use. By empowering individuals with real-time glucose data and personalized insights, CGM can play a pivotal role in transforming diabetes management and improving patient outcomes. As technology continues to evolve, CGM holds immense promise for shaping the future of diabetes care. As of June 22nd, 2025, these findings represent the latest advancements in Type 2 diabetes management, though continued research and development will undoubtedly bring further progress in the near future.
Be the first to comment